(6S)-6-(4-cyanophenyl)-4-methyl-2-oxo-N-propan-2-yl-3-[3-(trifluoromethyl)-phenyl]-5,6-dihydropyridine-1-carboxamide | 1050618-77-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (6S)-6-(4-cyanophenyl)-4-methyl-2-oxo-N-propan-2-yl-3-[3-(trifluoromethyl)-phenyl]-5,6-dihydropyridine-1-carboxamide
• 英文别名: (2S)-2-(4-cyanophenyl)-4-methyl-6-oxo-N-propan-2-yl-5-[3-(trifluoromethyl)phenyl]-2,3-dihydropyridine-1-carboxamide
• CAS: 1050618-77-3
• 化学式: C₂₄H₂₂F₃N₃O₂
• 分子量: 441.453
• InChiKey: NAEXIRHCJSWJOF-FQEVSTJZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  32
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  73.2
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  间三氟甲基苯乙酸 在 sodium methylate 、 sodium hydride 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 4.51h， 生成 (6S)-6-(4-cyanophenyl)-4-methyl-2-oxo-N-propan-2-yl-3-[3-(trifluoromethyl)-phenyl]-5,6-dihydropyridine-1-carboxamide
  参考文献：
  名称：

  WO2008/104752

  摘要：

  公开号：

文献信息

• Methods and pharmaceutical compositions for the treatment of bacterial infections in patients suffering from cirrhosis
  申请人：INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)

  公开号：US10201536B2

  公开（公告）日：2019-02-12

  The present invention relates to methods and pharmaceutical compositions for the treatment of bacterial infections in patients suffering from cirrhosis. In particular, the present invention relates to a method of treating bacterial infection in a patient suffering from cirrhosis comprising administering to the patient a therapeutically effective amount of a TLR7 and/or TLR8 agonist.

  本发明涉及治疗肝硬化患者细菌感染的方法和药物组合物。特别是，本发明涉及一种治疗肝硬化患者细菌感染的方法，包括向患者施用治疗有效量的TLR7和/或TLR8激动剂。
• METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF BACTERIAL INFECTIONS IN PATIENTS SUFFERING FROM CIRRHOSIS
  申请人：INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)

  公开号：US20180140597A1

  公开（公告）日：2018-05-24

  The present invention relates to methods and pharmaceutical compositions for the treatment of bacterial infections in patients suffering from cirrhosis. In particular, the present invention relates to a method of treating bacterial infection in a patient suffering from cirrhosis comprising administering to the patient a therapeutically effective amount of a TLR7 and/or TLR8 agonist.
• [EN] DIHYDROPYRIDONES AS ELASTASE INHIBITORS<br/>[FR] DIHYDROPYTIDONES INHIBITEURS D'ÉLASTASE
  申请人：ASTRAZENECA AB

  公开号：WO2008104752A1

  公开（公告）日：2008-09-04

  [EN] The invention provides compounds of formula wherein R¹, R², R³, R⁴, R⁵, R⁶, R⁷, X¹, X², X³ and X⁴ are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of human neutrophil elastase.
  [FR] La présente invention concerne des composés représentés par la formule dans laquelle R¹ à R⁷ et X¹ à X⁴ sont tels que définis dans la spécification, certains de leurs isomères optiques, racémates et tautomères, et certains de leurs sels pharmaceutiquement admis. L'invention concerne également des procédés d'élaboration correspondants, des compositions pharmaceutiques les contenants, et leur utilisation thérapeutique. Ces composés sont des inhibiteurs de l'élastase neutrophile humaine.
• [EN] METHODS AND COMPOSITIONS FOR THE TREATMENT OF A CHAGAS DISEASE<br/>[FR] MÉTHODES ET COMPOSITIONS POUR LE TRAITEMENT DE LA MALADIE DE CHAGAS
  申请人：BIOMED VALLEY DISCOVERIES

  公开号：WO2014186623A2

  公开（公告）日：2014-11-20

  The present invention provides, inter alia, methods for treating or ameliorating the effects of a Chagas disease. The methods include administering to a subject in need thereof an effective amount of a first active agent selected from the group consisting of a histamine-H1-receptor antagonist, a selective neutrophil elastase inhibitor, an ergot alkaloid derivative, an inhibitor of 3 β-hydroxysteroid dehydrogenase, a reversible acetylcholinesterase inhibitor, a protease inhibitor, an aldosterone antagonist, a naphthoquinone, and combinations thereof, and a second active agent, which is benznidazole. Also provided are compositions for treating or ameliorating the effects of a Chagas disease. The compositions include azelastine and benznidazole in amounts effective to treat or ameliorate the effect of a Chagas disease and a pharmaceutically acceptable carrier.